Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
NCT03259035Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jun 2018
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of FOLFOX, Capecitabine + oxaliplatin in rectal cancer, sponsored by Canadian Cancer Trials Group. Started Jun 2018; status: completed.
02
Drugs
FOLFOXCapecitabine + oxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03259035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03259035.